In today’s fast-paced world, maintaining optimal health has become a primary concern for many individuals. Diet and exercise ...

In the absence of any marketed drugs, investors are set to focus on BEAM's pipeline updates when it reports first-quarter 2025 earnings.

It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc.

Ultragenyx's strong revenue growth, diverse streams, and late-stage pipeline make it a standout in rare disease and gene ...

therapy for glycogen storage disease 1a. Roche has claimed a CE Mark in the EU for an AI algorithm that can help doctors decide whether patients with chest pain are having a heart attack.

In today’s fast-paced world, maintaining optimal health and wellness is more crucial than ever. Glycogen Balance emerges as a ...

Fecal microbiota from selected human donors was then transplanted into antibiotic-pretreated mice to assess changes in insulin sensitivity and glycogen storage. Gut bacterial diversity and density ...

It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP ...